|
1
|
Munkley J, Vodak D, Livermore KE, James K,
Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries
LW, et al: Glycosylation is an androgen-regulated process essential
for prostate cancer cell viability. EBioMedicine. 8:103–116. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Munkley J, McClurg UL, Livermore KE,
Ehrmann I, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries
LW, Leung HY, et al: The cancer-associated cell migration protein
TSPAN1 is under control of androgens and its upregulation increases
prostate cancer cell migration. Sci Rep. 7:52492017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ankerst DP and Thompson IM: Sensitivity
and specificity of prostate-specific antigen for prostate cancer
detection with high rates of biopsy verification. Arch Ital Urol
Androl. 78:125–129. 2006.PubMed/NCBI
|
|
5
|
Snoek R, Cheng H, Margiotti K, Wafa LA,
Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME and Rennie PS: In
vivo knockdown of the androgen receptor results in growth
inhibition and regression of well-established, castration-resistant
prostate tumors. Clin Cancer Res. 15:39–47. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nelson WG, De Marzo AM and Isaacs WB:
Prostate cancer. N Engl J Med. 349:366–381. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Bono JS, Oudard S, Ozguroglu M, Hansen
S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L,
et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic
castration-resistant prostate cancer progressing after docetaxel
treatment: A randomised open-label trial. Lancet. 376:1147–1154.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Parker C, Nilsson S, Heinrich D, Helle SI,
O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, et
al: Alpha emitter radium-223 and survival in metastatic prostate
cancer. N Engl J Med. 369:213–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grasso CS, Wu YM, Robinson DR, Cao X,
Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC,
et al: The mutational landscape of lethal castrate resistant
prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Robinson D, Van Allen EM, Wu YM, Schultz
N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC,
Attard G, et al: Integrative clinical genomics of advanced prostate
cancer. Cell. 161:1215–1228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumar A, White TA, MacKenzie AP, Clegg N,
Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, et al:
Exome sequencing identifies a spectrum of mutation frequencies in
advanced and lethal prostate cancers. Proc Natl Acad Sci USA.
108:17087–17092. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hiesberger T, Shao X, Gourley E, Reimann
A, Pontoglio M and Igarashi P: Role of the hepatocyte nuclear
factor-1beta (HNF-1beta) C-terminal domain in Pkhd1 (ARPKD) gene
transcription and renal cystogenesis. J Biol Chem. 280:10578–10586.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ross-Adams H, Ball S, Lawrenson K, Halim
S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S,
et al: HNF1B variants associate with promoter methylation and
regulate gene networks activated in prostate and ovarian cancer.
Oncotarget. 7:74734–74746. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Itkonen HM, Brown M, Urbanucci A, Tredwell
G, Lau Ho C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV,
et al: Lipid degradation promotes prostate cancer cell survival.
Oncotarget. 8:38264–38275. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Opoku-Acheampong AB, Unis D, Henningson
JN, Beck AP and Lindshield BL: Preventive and therapeutic efficacy
of finasteride and dutasteride in TRAMP mice. PLoS One.
8:e777382013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Senkel S, Lucas B, Klein-Hitpass L and
Ryffel GU: Identification of target genes of the transcription
factor HNF1beta and HNF1alpha in a human embryonic kidney cell
line. Biochim Biophys Acta. 1731:179–190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stevens VL, Ahn J, Sun J, Jacobs EJ, Moore
SC, Patel AV, Berndt SI, Albanes D and Hayes RB: HNF1B and JAZF1
genes, diabetes, and prostate cancer risk. Prostate. 70:601–607.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Itkonen HM, Engedal N, Babaie E, Luhr M,
Guldvik IJ, Minner S, Hohloch J, Tsourlakis MC, Schlomm T and Mills
IG: UAP1 is overexpressed in prostate cancer and is protective
against inhibitors of N-linked glycosylation. Oncogene.
34:3744–3750. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Itkonen HM, Minner S, Guldvik IJ, Sandmann
MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T and Mills IG:
O-GlcNAc transferase integrates metabolic pathways to regulate the
stability of c-MYC in human prostate cancer cells. Cancer Res.
73:5277–5287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gelman IH: How the TRAMP model
revolutionized the study of prostate cancer progression. Cancer
Res. 76:6137–6139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gingrich JR, Barrios RJ, Morton RA, Boyce
BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM and Greenberg
NM: Metastatic prostate cancer in a transgenic mouse. Cancer Res.
56:4096–4102. 1996.PubMed/NCBI
|
|
22
|
Wei L, Wang J, Lampert E, Schlanger S,
DePriest AD, Hu Q, Gomez EC, Murakam M, Glenn ST, Conroy J, et al:
Intratumoral and intertumoral genomic heterogeneity of multifocal
localized prostate cancer impacts molecular classifications and
genomic prognosticators. Eur Urol. 71:183–192. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu DD, Guo SW, Jing YY, Dong YL and Wei
LX: A review on hepatocyte nuclear factor-1beta and tumor. Cell
Biosci. 5:582015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu YL, Zhong D, Pang F, Ning QY, Zhang YY,
Li G, Wu JZ and Mo ZN: HNF1b is involved in prostate cancer risk
via modulating androgenic hormone effects and coordination with
other genes. Genet Mol Res. 12:1327–1335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mallik I, Davila M, Tapia T, Schanen B and
Chakrabarti R: Androgen regulates Cdc6 transcription through
interactions between androgen receptor and E2F transcription factor
in prostate cancer cells. Biochim Biophys Acta. 1783:1737–1744.
2008. View Article : Google Scholar : PubMed/NCBI
|
